H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

Core Insights - Stoke Therapeutics, Inc. (NASDAQ:STOK) is identified as a promising growth stock with a Buy rating and a price target of $35 set by H.C. Wainwright analyst Ananda Ghosh [1][2] Company Overview - Stoke Therapeutics is a biotech company focused on developing RNA-based medicines aimed at increasing protein expression to treat various diseases [3] - The company's lead drug, Zorevunersen, is specifically designed for treating Dravet syndrome [3] Drug Potential - Zorevunersen has shown promising results in a 36-month open-label extension study, indicating a long-term reduction in major motor seizure frequency and improvements in cognitive and behavioral aspects [2] - The drug is positioned to potentially become the first disease-modifying therapy for Dravet syndrome, differentiating itself from existing treatments that primarily focus on symptomatic relief [2][3]